KLRK1 and cancer: NKG2D-DAP10-CD3ζ-expressing NK-cells were found to exhibit a remarkably strong antitumor potential in several different cancers including breast cancer, hepatocellular carcinoma (HCC), osteosarcoma and pancreatic cancer (97).